Evotec (EVO) Stock: Buy, Sell, or Hold?
EVO - Evotec SE American Depositary Shares
$1.50
-0.04 (-2.60%)
âŧ
5d:
+8.7%
30d:
-1.96%
90d:
-21.87%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: May 06, 2026
0d
Get Alerted When EVO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: EVO is fairly priced but lacks strong directional signals. At -6.9% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: EVO is fairly priced but lacks strong directional signals. At -6.9% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: EVO is currently trading at $1.50, which is considered slightly low relative to its 30-day fair value range of $1.45 to $1.64. From a valuation perspective, the stock is trading at a discount (Forward PE: 21.4) compared to its historical average (26.6). Remarkably, the market is currently pricing in an annual earnings decline of 6.9% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, EVO is in a strong downtrend. Immediate support is located at $1.33, while resistance sits at $1.56.
Market Sentiment: EVO scores 70/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $4.23 (+181.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EVO is in a strong downtrend. Immediate support is located at $1.33, while resistance sits at $1.56.
Market Sentiment: EVO scores 70/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $4.23 (+181.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.45 -
$1.64
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
90.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (70/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 181.8% below Wall St target ($4.23)
- WARNING: Composite score 49/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.45 -
$1.64
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$1.33
Resistance Level
$1.56
Current Trend
Strong Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
21.43
Wall Street Target
$4.23
(+181.8%)
Revenue Growth (YoY)
-16.2%
Profit Margin
-27.5%
Valuation Discount vs History
-6.9% cheaper
PE vs Historical
21.4 vs 26.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-6.9%
(market-implied from PE analysis)
1-Year Target
$1.40
(-7%)
2-Year Target
$1.30
(-13%)
3-Year Target
$1.21
(-19%)
3-Yr Target (if PE normalizes)
(PE: 21â27)
$1.50
(+0%)
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 21.4 to 26.6
Stabilization Target:
$1.86
(+24.1%)
PE Expansion Potential:
+24.1%
Share & Embed Analysis
Last updated: October 24, 2026 6:12 PM ET
Data refreshes hourly during market hours. Next update: 7:12 PM
Data refreshes hourly during market hours. Next update: 7:12 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EVO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
29 analysts |
$207 | 56 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 47 HOLD |
|
AQST
Aquestive Therapeutics IâĻ |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$56 | 38 SELL |
|
AMLX
Amylyx Pharmaceuticals IâĻ |
STRONG BUY
12 analysts |
$43 | 54 HOLD |
